Quick access to key HIV drug hinges on waiver of local clinical trials: Experts

Faster access to HIV drug lenacapavir in India hinges on the waiver of local clinical trials. Six companies, including three from India, have non-exclusive, royalty-free licenses to produce generic versions. They must apply for waivers to supply the drug locally and in 120 low- and middle-income countries. Approval from the drug regulator is crucial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/35L7eW2
via IFTTT